Repotrectinib for kids with certain cancer gene changes
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific ROS1 or NTRK1-3 genetic change confirmed by lab testing (done in an accredited lab).
- Your age must be under 12 years (Phase 1) or 12 to 25 years (Phase 2).
- You must have measurable cancer seen on scans (or, for brain tumors, measurable disease by the study’s brain-tumor rules).
- Any side effects from past cancer treatments (except hair loss) must be mostly gone or mild (Grade 1 or less).
- If you have a brain tumor or brain spread, your nervous system must be stable and steroid dose must be stable or decreasing for at least 7 days.
- Your body must be healthy enough for treatment: blood counts and organ function must meet lab limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
This study tracks the safety and effects of the drug repotrectinib in children aged 4 to under 18 with certain tumors that have a specific genetic change (NTRK fusion). The goal is to see how well the drug works in everyday medical practice in Japan.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.